Reviews, Commentaries, etc. - KANAI Yae

【クリニカルシークエンスと病理診断】ゲノム研究・ゲノム医療のための病理組織検体品質管理

金井 弥栄

病理と臨床 ((株)文光堂)  36 ( 7 ) 635 - 640 2018.07

Other, Single Work,  ISSN  0287-3745

肝硬変から肝癌へ その臨床的・病理学的背景とメカニズム 前がん段階から肝細胞がんに至るDNAメチル化異常

金井 弥栄

日本病理学会会誌 ((一社)日本病理学会)  107 ( 1 ) 195 - 195 2018.04

Other, Single Work,  ISSN  0300-9181

ゲノム・エピゲノム統合解析による胃発がん分子機構の解明

楊 夢ハン, 新井 恵吏, 坂本 裕美, 戸塚 裕彦, 谷口 浩和, 吉田 輝彦, 金井 弥栄

日本病理学会会誌 ((一社)日本病理学会)  107 ( 1 ) 431 - 431 2018.04

Other, Joint Work,  ISSN  0300-9181

メチローム解析に基づいた胃がん特異的DNAメチル化マーカーの探索

亀山 真一, 新井 恵吏, 田 迎, 伊藤 菜々子, 澁谷 亜矢子, 谷口 浩和, 吉田 輝彦, 金井 弥栄

日本病理学会会誌 ((一社)日本病理学会)  107 ( 1 ) 518 - 518 2018.04

Other, Joint Work,  ISSN  0300-9181

肝炎ウイルス感染・アルコール多飲・脂肪肝を伴わない肝発がんのエピゲノム異常

牧内 里美, 新井 恵吏, 藏本 純子, 田 迎, 深町 幸宏, 高橋 順子, 平岡 伸介, 吉田 輝彦, 金井 弥栄

日本病理学会会誌 ((一社)日本病理学会)  107 ( 1 ) 369 - 369 2018.04

Other, Joint Work,  ISSN  0300-9181

A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/β1i.

Hayashi T, Kawano M, Sano K, Ichimura T, Gur G, Yaish P, Zharhary D, Kanai Y, Tonegawa S, Shiozawa T, Yaegashi N, Konishi I

Chinese clinical oncology (Chinese Clinical Oncology)  6 ( 2 ) 1 - 3 2017.04

ISSN  23043865

• Access to Document (DOI)

The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery

Stunnenberg H.G., Abrignani S., Adams D., de Almeida M., Altucci L., Amin V., Amit I., Antonarakis S.E., Aparicio S., Arima T., Arrigoni L., Arts R., Asnafi V., Badosa M.E., Bae J.B., Bassler K., Beck S., Berkman B., Bernstein B.E., Bilenky M., Bird A., Bock C., Boehm B., Bourque G., Breeze C.E., Brors B., Bujold D., Burren O., Bussemakers M.J., Butterworth A., Campo E., Carrillo-de-Santa-Pau E., Chadwick L., Chan K.M., Chen W., Cheung T.H., Chiapperino L., Choi N.H., Chung H.R., Clarke L., Connors J.M., Cronet P., Danesh J., Dermitzakis M., Drewes G., Durek P., Dyke S., Dylag T., Eaves C.J., Ebert P., Eils R., Eils J., Ennis C.A., Enver T., Feingold E.A., Felder B., Ferguson-Smith A., Fitzgibbon J., Flicek P., Foo R.S.Y., Fraser P., Frontini M., Furlong E., Gakkhar S., Gasparoni N., Gasparoni G., Geschwind D.H., Glažar P., Graf T., Grosveld F., Guan X.Y., Guigo R., Gut I.G., Hamann A., Han B.G., Harris R.A., Heath S., Helin K., Hengstler J.G., Heravi-Moussavi A., Herrup K., Hill S., Hilton J.A., Hitz B.C., Horsthemke B., Hu M., Hwang J.Y., Ip N.Y., Ito T., Javierre B.M., Jenko S., Jenuwein T., Joly Y., Jones S.J.M., Kanai Y., Kang H.G., Karsan A., Kiemer A.K., Kim S.C., Kim B.J.

Cell (Cell)  167 ( 5 ) 1145 - 1149 2016.11

ISSN  00928674

　View Summary

© 2016 Elsevier Inc. The International Human Epigenome Consortium (IHEC) coordinates the generation of a catalog of high-resolution reference epigenomes of major primary human cell types. The studies now presented (see the Cell Press IHEC web portal at http://www.cell.com/consortium/IHEC) highlight the coordinated achievements of IHEC teams to gather and interpret comprehensive epigenomic datasets to gain insights in the epigenetic control of cell states relevant for human health and disease. PaperClip

• Access to Document (DOI)

Biological characterization of soft tissue sarcomas

Takuma Hayashi, Akiko Horiuchi, Kenji Sano, Yae Kanai, Nobuo Yaegashi, Hiroyuki Aburatani, Ikuo Konishi

Annals of Translational Medicine (AME Publishing Company)  3 ( 22 ) 368 2015.12

ISSN  23055839

　View Summary

Soft tissue sarcomas are neoplastic malignancies that typically arise in tissues of mesenchymal origin. The identification of novel molecular mechanisms leading to mesenchymal transformation and the establishment of new therapies and diagnostic biomarker has been hampered by several critical factors. First, malignant soft tissue sarcomas are rarely observed in the clinic with fewer than 15,000 newly cases diagnosed each year in the United States. Another complicating factor is that soft tissue sarcomas are extremely heterogeneous as they arise in a multitude of tissues from many different cell lineages. The scarcity of clinical materials coupled with its inherent heterogeneity creates a challenging experimental environment for clinicians and scientists. Faced with these challenges, there has been extremely limited advancement in clinical treatment options available to patients as compared to other malignant tumours. In order to glean insight into the pathobiology of soft tissue sarcomas, scientists are now using mouse models whose genomes have been specifically tailored to carry gene deletions, gene amplifications, and somatic mutations commonly observed in human soft tissue sarcomas. The use of these model organisms has been successful in increasing our knowledge and understanding of how alterations in relevant oncogenic and/or tumour suppressive signal cascades, i.e., interferon-γ (IFN-γ), tumour protein 53 (TP53) and/or retinoblastoma (RB) pathway directly impact sarcomagenesis. It is the goal of many in the physiological community that the use of several mouse models will serve as powerful in vivo tools for further understanding of sarcomagenesis and potentially identify new diagnostic biomarker and therapeutic strategies against human soft tissue sarcomas.

• Access to Document (DOI)

Multilayer-omics analyses of human cancers: exploration of bionnarkers and drug targets based on the activities of the International Human Epigenome Consortium

Yae Kanai, Eri Arai

FRONTIERS IN GENETICS (FRONTIERS MEDIA SA)  5 ( FEB ) 1330 - 1342 2014

ISSN  1664-8021

　View Summary

Epigenetic alterations consisting mainly of DNA methylation alterations and histone modification alterations are frequently observed in cancers associated with chronic inflammation and/or persistent infection with viruses or other pathogenic microorganisms, or with cigarette smoking. Accumulating evidence suggests that alterations of DNA methylation are involved even in the early and precancerous stages. On the other hand, in patients with cancers, aberrant DNA methylation is frequently associated with tumor aggressiveness and poor patient outcome. Recently, epigenome alterations have been attracting a great deal of attention from researchers who are focusing on not only cancers but also neuronal, immune and metabolic disorders. In order to accurately identify disease-specific epigenome profiles that could be potentially applicable for disease prevention, diagnosis and therapy, strict comparison with standard epigenome profiles of normal tissues is indispensable. However, epigenome mechanisms show heterogeneity among tissues and cell lineages. Therefore, it is not easy to obtain a comprehensive picture of standard epigenome profiles of normal tissues. In 2010, the International Human Epigenome Consortium (IHEC) was established to coordinate the production of reference maps of human epigenomes for key cellular states. In order to gain substantial coverage of the human epigenome, the IHEC has set an ambitious goal to decipher at least 1000 epigenomes within the next 7-10 years. We consider that pathway analysis using genes showing multilayer-omics abnormalities, including genome, epigenome, transcriptome, proteome and metabolome abnormalities, may be useful for elucidating the molecular background of pathogenesis and for exploring possible therapeutic targets for each disease.

• Access to Document (DOI)

Morules in Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas

Yoko Tateno, Minoru Esaki, Kazuaki Shimada, Hidenori Ojima, Yae Kanai, Nobuyoshi Hiraoka

PANCREAS (LIPPINCOTT WILLIAMS & WILKINS)  41 ( 4 ) 651 - 652 2012.05

ISSN  08853177

• Access to Document (DOI)

Letter to the Editor

Nara S., Shimada K., Kosuge T., Kanai Y., Hiraoka N.

American Journal of Surgical Pathology (American Journal of Surgical Pathology)  33 ( 2 ) 321 - 322 2009.02

ISSN  01475185

• Access to Document (DOI)

Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray

Yae Kanai

LANCET ONCOLOGY (LANCET LTD)  9 ( 2 ) 91 - 93 2008.02

ISSN  14702045

• Access to Document (DOI)

Erratum: Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene (Laboratory Investigation (2005) 85 (895-907) DOI: 10.1038/sj.labinvest.3700268))

Chihara Y., Sugano K., Kobayashi A., Kanai Y., Yamamoto H., Nakazono M., Fujimoto H., Kakizoe T., Fujimoto K., Hirohashi S., Hirao Y.

Laboratory Investigation (Laboratory Investigation)  85 ( 8 )  2005.08

ISSN  00236837

• Access to Document (DOI)

Malignant mixed epithelial and stromal tumours of the kidney: A report of the first two cases with a fatal clinical outcome [5]

Nakagawa T., Kanai Y., Fujimoto H., Kitamura H., Furukawa H., Maeda S., Oyama T., Takesaki T., Hasegawa T.

Histopathology (Histopathology)  44 ( 3 ) 302 - 304 2004.03

ISSN  03090167

• Access to Document (DOI)

Metastatic renal cell carcinoma to the gallbladder: color Doppler sonography and CT findings.

Furukawa H., Mizuguchi Y., Kanai Y., Mukai K.

AJR. American journal of roentgenology (AJR. American journal of roentgenology)  169 ( 5 ) 1466 - 1467 1997.11

ISSN  0361803X

• Access to Document (DOI)

Arteriovenous hemangioma of the gallbladder: CT and pathologic findings.

Furukawa H., Kanai Y., Mukai K., Yamasaki S.

AJR. American journal of roentgenology (AJR. American journal of roentgenology)  168 ( 5 )  1997.05

ISSN  0361803X

• Access to Document (DOI)